Effects of levosimendan in patients with severe functional mitral regurgitation undergoing MitraClip implantation

Journal of Cardiovascular Medicine

Volumn 18, Issue 9, 2017, Pages 679-686

  Giannini, Cristina ^a   Petronio, Anna S ^a   Fiorelli, Francesca ^a   Liga, Riccardo ^a   Spontoni, Paolo ^a   De Carlo, Marco ^a   Marraccini, Emilia ^a   Pieroni, Andrea ^a   Guarracino, Fabio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

functional mitral regurgitation; heart failure; levosimendan therapy; MitraClip implantation

Indexed keywords

LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE REGISTRY; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FUNCTIONAL MITRAL REGURGITATION; FUNCTIONAL STATUS; HEART FAILURE; HEART VALVE REPLACEMENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; IMPLANTABLE CLIP; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; OPERATION DURATION; PERCUTANEOUS MITRAL VALVE REPAIR; PERIOPERATIVE PERIOD; PROGNOSIS; PROPENSITY SCORE; PULSE WAVE; COMPLICATION; CONTROLLED CLINICAL TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PYRIDAZINES;

EID: 85021796631     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000537     Document Type: Article

References (34)

1. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009; 373:1382-1394.
2. De Bonis M, Maisano F, La Canna G, Alfieri O. Treatment and management of mitral regurgitation. Nat Rev Cardiol 2011; 9:133-146.
3. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451-2496.
4. Crabtree TD, Bailey MS, Moon MR, et al. Recurrent mitral regurgitation and risk factors for early and late mortality after mitral valve repair for functional ischemic mitral regurgitation. Ann Thorac Surg 2008; 85:1537-1542; discussion 1542-1543.
5. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:e521-e643.
6. D'ascenzo F, Moretti C, Marra WG, et al. Meta-analysis of the usefulness of Mitraclip in patients with functional mitral regurgitation. Am J Cardiol 2015; 116:325-331.
7. Giannini C, Fiorelli F, De Carlo M, et al. Comparison of percutaneous mitral valve repair versus conservative treatment in severe functional mitral regurgitation. Am J Cardiol 2016; 117:271-277.
8. Giannini C, Petronio AS, De Carlo M, et al. Integrated reverse left and right ventricular remodelling after MitraClip implantation in functional mitral regurgitation: an echocardiographic study. Eur Heart J Cardiovasc Imaging 2014; 15:95-103.
9. Neuss M, Schau T, Schoepp M, et al. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail 2013; 15:786-795.
10. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk study. J Am Coll Cardiol 2012; 59:130-139.
11. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol 2014; 64:172-181.
12. Capodanno D, Adamo M, Barbanti M, et al. Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. Am Heart J 2015; 170:187-195.
13. Freixa X, Hernandez M, Farrero M, et al. Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction. Int J Cardiol 2016; 202:517-518.
14. TollerW,Guarracino F, Landoni G.Reply to Carev et al. 'Useful supplement to the best practice of using levosimendan in cardiac surgery patients: 2.5mg intravenous bolus for cardiopulmonary resuscitation during perioperative cardiac arrest'. J Cardiothorac Vasc Anesth 2013; 27:e77-e78.
15. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013; 27:1224-1232.
16. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364:1395-1406.
17. Guarracino F, Baldassarri R, Ferro B, et al. Transesophageal echocardiography during MitraClip1 procedure. Anesth Analg 2014; 118:1188-1196.
18. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009; 54:686-694.
19. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1-39.e14.
20. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESSEU, a prospective, multicenter, nonrandomized postapproval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013; 62:1052-1061.
21. Swaans MJ, Bakker AL, Alipour A, et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgicalrisk patients. JACC Cardiovasc Interv 2014; 7:875-881.
22. Taramasso M, Denti P, Buzzatti N, et al. Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience. Eur J Cardiothorac Surg 2012; 42:920-926.
23. Franzen O, van der Heyden J, Baldus S, et al. MitraClip1 therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 2011; 13:569-576.
24. Pleger ST, Schulz-Scho? nhagen M, Geis N, et al. One year clinical efficacy and reverse cardiac remodelling in patients with severe mitral regurgitation and reduced ejection fraction after MitraClip implantation. Eur J Heart Fail 2013; 15:919-927.
25. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012; 17:125-130.
26. Tasouli A, Papadopoulos K, Antoniou T, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use. Eur J Cardiothorac Surg 2007; 32:629-633.
27. Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376:2021-2031.
28. Scandura S, Dipasqua F, Gargiulo G, et al. Early results of MitraClip system implantation by real-time three-dimensional speckle-tracking left ventricle analysis. J Cardiovasc Med (Hagerstown) 2016; 17:843-849.
29. Kaneko H, Neuss M, Weissenborn J, Butter C. Prognostic significance of right ventricular dysfunction in patients with functional mitral regurgitation undergoing MitraClip. Am J Cardiol 2016; 118:1717-1722.
30. Di Mauro M, Calafiore AM, Penco M, Romano S, Di Giammarco G, Gallina S. Mitral valve repair for dilated cardiomyopathy: predictive role of right ventricular dysfunction. Eur Heart J 2007; 28:2510-2516.
31. Dini FL, Conti U, Fontanive P, et al. Right ventricular dysfunction is a major predictor of outcome in patients with moderate to severe mitral regurgitation and left ventricular dysfunction. Am Heart J 2007; 154:172-179.
32. Giannini C, Fiorelli F, Colombo A, et al. Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. Int J Cardiol 2016; 223:574-580.
33. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 2006; 98:1489-1492.
34. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 2006; 92:1768-1772.